期刊文献+

局部晚期鼻咽癌不同调强技术的剂量学比较 被引量:3

下载PDF
导出
摘要 目的 研究局部晚期鼻咽癌常规固定野调强(IMRT)、单弧容积旋转调强(SA-VMAT)及双弧容积旋转调强(DA-VMAT)3种调强放疗技术的剂量学差异.方法 30例局部晚期鼻咽癌患者,以相同处方剂量和目标进行9野IMRT、SA-VMAT及DA-VMAT计划设计.比较3种计划靶区(PTV)剂量参数、适形度指数(CI)和均匀性指数(HI)及危及器官(OAR)剂量参数、机器跳数(MU)、治疗时间.结果 3种计划均能满足临床剂量学要求.在鼻咽部原发癌及颈转移淋巴结计划靶区(PGTV)靶区,DA-VMAT和IMRT的CI优于SA-VMAT(P<0.05).在PTV1靶区,DA-VMAT的D98值高于SA-VMAT(P<0.05);DA-VMAT和IMRT的HI优于SA-VMAT(P<0.05).其余数值均无差异.危及器官方面,DA-VMAT脊髓最大剂量较IMRT及SA-VMAT剂量明显低(P<0.05);DA-VMAT及IMRT腮腺平均剂量均较SA-VMAT明显低(P<0.05).IMRT的MU明显多于SA-VMAT及DA-VMAT(P<0.05).IMRT的治疗时间明显长于SA-VMAT及DA-VMAT(P<0.05).结论 在局部晚期鼻咽癌放疗中,3种计划在靶区覆盖和危及器官保护上都可以达到临床要求.DA-VMAT计划可以达到或略优于IMRT计划的靶区剂量分布,并能更好地保护脊髓,减少治疗时间.
出处 《中国老年学杂志》 CAS 北大核心 2020年第9期1838-1841,共4页 Chinese Journal of Gerontology
  • 相关文献

参考文献4

二级参考文献50

  • 1蔡勇,何玉香,韩树奎,吴昊,弓健,徐博.直肠癌盆腔常规放疗与三维适形放疗的剂量学研究[J].中华放射肿瘤学杂志,2007,16(3):201-205. 被引量:20
  • 2[4]JP Xiao, GZ Xu, YJ Miao. Fractionated stereotactic radio therapy for 50 patients with recurrent or residual nasopharyngeal carcinoma [J]. Int J Rad Oncol Biol Phys, 2001, 51(1):164-170.
  • 3[5]Le QT, Tate D, Koong A, et al. Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2003, 56(4):1046-1054.
  • 4[6]N Lee, P Xia, JM Quivey, et al. Intensity-modulated ra diotherapy in the treatment of nasopharyngeal carcinoma: an update of USCF experience [J].J Radiat Oncol Biol Phys, 2002, 53(1):12-22.
  • 5[10]CH Shu, H Cheng, JF Lirng, et al. Salvage surgery for recurrent nasopharyngeal carcinoma[J]. The Laryngoscope, 2000,110(9): 1483-1488.
  • 6[11]WWK King, PKM Ku, C Mork, et al. Nasopharyngectomy in the treatment of recurrent nasopharyngeal carcinoma: a twelve-year experience[J]. Head and Neck, 2000, 22(3): 215-222.
  • 7[12]International nasopharynx cancer study group. Preliminary results of a randomized trial comparing neoadjurant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs radiotherapy alone in satge Ⅳ(≥N2M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival [J]. Int J Radiat Oncol BiolPhys, 1996,3 5:463-469.
  • 8[13]Chua DT, Sham JS, Choy D, et al. Preliminary report of the Asian Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy along in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharyngeal Cancer Study Group[J]. Cancer, 1998, 83(11):2270-2283.
  • 9[15]Chua DT, Sham JS, Wei WI, et al. Control of regional metastasis after induction chemotherapy and radiotherapy for nasopharyngeal carcinoma[J]. Head Neck, 2002, 24 (4):350-360.
  • 10[16]Lin JC, Jan JS, Liang WM, et al. Phase Ⅲstudy of concurrent chemoradiotherapy versus radiotherapy alone for ad vanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival [J]. J Clin Oncol, 2003 , 21:631-637.

共引文献30

同被引文献28

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部